Suicide gene therapy of sarcoma cell lines using recombinant adeno-associated virus 2 vectors

Area of Science:

• Oncology
• Gene Therapy
• Virology

Background:

• Soft-tissue sarcomas are mesenchymal tumors with poor response to conventional chemotherapy.
• Suicide gene therapy presents a potential alternative treatment strategy for these challenging cancers.

Purpose of the Study:

• To evaluate the efficacy of recombinant adeno-associated virus 2 (rAAV-2) based suicide gene therapy in human sarcoma cell lines.
• To compare different promoter activities (CMV vs. EF1alpha) in rAAV-2 suicide vectors for sarcoma treatment.

Main Methods:

• In vitro transduction of human sarcoma cell lines (HS-1, HT-1080, RD-ES, SK-N-MC, A-204, WSKL-1) with rAAV-2 vectors carrying the thymidine kinase (TK) gene.
• Treatment of transduced cells with ganciclovir and assessment of cell viability.
• Establishment of xenotransplantation tumor models (intraperitoneal, subcutaneous) in immunodeficient mice using the HS-1 cell line.

Main Results:

• Human sarcoma cell lines demonstrated high susceptibility to rAAV-2 suicide vectors.
• The EF1alpha promoter resulted in higher transgene expression compared to the CMV promoter.
• Complete eradication of transduced sarcoma cells was achieved in vitro upon ganciclovir exposure.
• In vivo, mice treated with rAAV-2-EF1alpha-TK/eGFP and ganciclovir survived over 5 months, whereas control groups succumbed within 1 month.

Conclusions:

• rAAV-2-based suicide gene therapy, particularly with the EF1alpha promoter, is a highly effective strategy against human sarcomas.
• This approach holds significant promise for the future development of novel sarcoma treatments.